Omeza OCM for Diabetic Foot Ulcers | Fortify Medical
Authorized Distributor — Fortify Medical

The Wound Matrix That
Serious Practices
Are Talking About

Omeza OCM is an FDA 510(k)-cleared wound matrix designed to support all phases of healing in diabetic foot ulcers, venous ulcers, pressure ulcers, and complex chronic wounds — with CMS-exempt positioning that gives forward-thinking practices a distinct advantage.

FDA 510(k) Cleared
CMS-Exempt Positioning
Nationwide Coverage
24-Hour Response

Request Information

A Fortify Medical representative will follow up within 24 hours.

$2,050
Carrier-priced reimbursement
per vial positioning
CMS-Exempt
Non-sheet product, exempt from
$127.14/cm² flat rate cap
FDA 510(k)
Cleared wound matrix
for multiple wound types
4 Phases
Comprehensive wound healing
support in a single product

About Omeza OCM

A Different Approach to Chronic Wound Management

Omeza OCM is positioned as a first-of-its-kind drug-device combination wound matrix made with cold water fish peptides. Unlike sheet-based skin substitutes, OCM is an amorphous solid designed to conform to irregular wound beds and support all four phases of wound healing in a single application.

  • Designed to decrease inflammation and reduce biofilm impact
  • Supports proliferation and tissue signaling
  • Provides scaffolding for skin remodeling
  • Single-use, disposable vials — convenient for clinical settings
  • Indicated for diabetic ulcers, venous ulcers, pressure ulcers, surgical wounds, trauma wounds, and more
How Does OCM Work — drug device combination wound matrix

How It Works

A First-of-Its-Kind Drug-Device Combination

Omeza OCM™ is created through a proprietary process that produces an amorphous solid capable of conforming to the wound bed — including tunnels and undermined areas — providing comprehensive support across all healing phases.

  • Contains cold water fish peptides — building blocks for tissue regeneration
  • Pharmaceutical-grade components proven non-cytotoxic
  • Reduces inflammation & biofilm impact on the wound bed
  • Increases proliferation and supports skin remodeling
  • Treats most types of chronic wounds in a single application

Clinical Evidence

Real Results Backed by Clinical Data

Omeza OCM is supported by a registered clinical study and growing provider feedback across wound care specialties. With over 60% positive application response rates reported, OCM delivers measurable outcomes in stalled and chronic wounds.

  • Registered study on ClinicalTrials.gov — NCT07161830
  • FDA 510(k) cleared for 8 wound type indications
  • Documented outcomes in diabetic, venous & pressure ulcers
  • Provider-reported healing in wounds stalled over 1 year
Omeza OCM Clinical Evidence Data

Comprehensive Wound Healing

Four Phases. One Product.

OCM is designed to address the key biological needs across all phases of wound healing — something most single-mechanism products cannot provide.

01
Decrease Inflammation

Reduces biofilm formation and supports a healthy inflammatory response to prepare the wound bed for healing.

02
Increase Proliferation

Provides molecules that signal tissues to grow and proliferate, accelerating the rebuilding of wound architecture.

03
Support Remodeling

Delivers scaffolding for skin to regrow on, supporting the structural restoration of tissue layers.

04
Reduce Biofilm Impact

Inhibits bacterial colonization and disrupts biofilm formation in chronic wounds where infection risk is elevated.

Practice Support

Built for Every Wound Care Setting

Fortify Medical supports providers across all major care environments.

Podiatrists

Support for diabetic foot ulcers, venous leg ulcers, and complex chronic wound cases.

Wound Care Centers

Resources for teams managing high-acuity, hard-to-heal chronic wounds at scale.

Mobile Wound Care

Information for providers serving patients across SNFs, home settings, and assisted living.

SNF / LTC Facilities

Product information for teams managing pressure ulcers in long-term care settings.

Dermatology

Resources for chronic wounds, venous stasis ulcers, and difficult wound management.

Vascular Surgery

Support for post-operative wounds, vascular ulcers, and complex wound management.

Plastic Surgery

Wound matrix support for surgical wounds, trauma wounds, and complex reconstructive cases.

Primary Care

Wound management resources for primary care physicians supporting chronic wound populations.

Provider Feedback

What Wound Care Leaders Are Saying

Feedback from clinicians managing real patients in podiatry, mobile wound care, and wound care center settings.

★★★★★

"Omeza collagen matrix is easily applied, easily maintained and nearly every patient with whom we've used it has gone on to improvement or full healing within the 3rd or 4th application."

Randall Kline, DPM, FACFAS, FAPWCA
Allied Bone and Joint
★★★★★

"After the first two treatments, I was most impressed by the positive qualitative change to the wound bed with robust granulation tissue forming. The wound quickly epithelialized and was healed."

Dr. Michael Lacqua, MD MBA
Medical Director, The Center for Wound Healing
★★★★★

"After 37 years of wound care experience, having tried everything in a wound care center setting, I can only suggest drop what you are using and try Omeza. The results are astounding."

Gregory A. Black, DPM
Sylvania Podiatry, Sylvania, Ohio
★★★★★

"Variable application concept, lidocaine, collagen (matrix), skin protectant, with an easy application process. Amazing results for my patients with chronic non-healing wounds!"

Dr. Anthony J. LaLama
Foot and Ankle Surgeon, Premier Foot & Ankle
★★★★★

"After about three months of using Omeza, I can finally say my patient's wound is healed. Before using Omeza, the patient's wound had stalled in healing, and this amazing product definitely helped kickstart the healing process."

Oscar Rojas, DPM
Barry University Foot and Ankle Institute
★★★★★

"I went into our case study looking to improve skin and wounds on long term patients. The response to the Omeza treatment protocol was greater than expected and healed 3 wounds that were present for greater than a year."

Carmen Hudson, MD, FACS, CWSP
Medical Director, United Wound Healing

Reimbursement Positioning

The Reimbursement Advantage That Sets OCM Apart

While most advanced wound products are subject to the flat $127.14/cm² CMS cap, Omeza OCM is positioned as a non-sheet product that may qualify for carrier-priced reimbursement through local Medicare Administrative Contractors.

Most Competitors
$127.14/cm²
CMS Capped Rate
  • Limited by pricing cap
  • Reduced reimbursement
  • Financial uncertainty
  • Restricted patient access
Omeza OCM
$2,050/vial
CMS-Exempt Positioning
  • Carrier-priced by local MACs
  • Consistent reimbursement
  • Practice financial stability
  • Continued patient access
For Providers

Stable reimbursement positioning means you can continue offering advanced wound care without financial uncertainty.

For Patients

Continued access to comprehensive wound healing technology without restrictions imposed by pricing caps.

For Your Practice

A competitive advantage with one of the few advanced wound care products exempt from the new flat rate cap.

Common Questions

Frequently Asked Questions

Omeza OCM is an FDA 510(k)-cleared wound matrix described as a first-of-its-kind drug-device combination product made with cold water fish peptides. It supports all phases of wound healing: inflammation reduction, proliferation, remodeling, and biofilm management.
Per official Omeza product information, OCM is indicated for: diabetic ulcers, venous ulcers, pressure ulcers, chronic vascular ulcers, tunneled and undermined wounds, surgical wounds, trauma wounds, and draining wounds.
Omeza OCM is positioned as a non-sheet product that may qualify for carrier-priced reimbursement through local MACs, distinct from the flat $127.14/cm² rate applied to sheet-based skin substitutes. Practices should verify current reimbursement status independently.
Fortify Medical is an authorized distributor of Omeza OCM, providing product information, clinical resources, and rep-level support to wound care practices nationwide. Our team handles direct practice inquiries with a 24-hour response commitment.
Yes. A registered study evaluating OCM combined with standard of care in the treatment of diabetic foot ulcers is listed on ClinicalTrials.gov (NCT07161830). Multiple provider testimonials are also available from podiatrists, wound care center medical directors, and DPMs.
Use the form at the top of this page or call us directly at (864) 387-8433. A representative will respond within 24 hours.

Our Team

About Fortify Medical

Fortify Medical is an authorized distributor of Omeza OCM, dedicated to supporting wound care practices nationwide with clinical resources, reimbursement guidance, and direct representative access.

Heather Bower MBA — Healthcare Administration, Fortify Medical
Healthcare Administration

Heather Bower

M.B.A — Healthcare Administration

Max Cavaliere — Medical Sales Executive, Fortify Medical
Medical Sales Executive

Max Cavaliere

Medical Sales Executive

Authorized Distributor

Committed to Your Practice's Success

Fortify Medical provides product information, clinical resources, reimbursement guidance, and direct representative support to wound care practices nationwide. Our team handles direct practice inquiries with a 24-hour response commitment.

Ready to Evaluate OCM?

See Whether Omeza OCM Is Right
for Your Practice

Talk with a Fortify Medical representative about product information, clinical resources, and reimbursement support for your practice.